FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2480201404> ?p ?o ?g. }

• W2480201404 endingPage "3748" @default.
• W2480201404 startingPage "3740" @default.
• W2480201404 abstract "Purpose Patients with extensive-stage disease small-cell lung cancer (SCLC) have poor survival outcomes despite first-line chemotherapy with etoposide and platinum. This randomized, double-blind phase III study evaluated the efficacy and safety of ipilimumab or placebo plus etoposide and platinum in patients with newly diagnosed extensive-stage disease SCLC. Patients and Methods Patients were randomly assigned at a ratio of one to one to receive chemotherapy with etoposide and platinum (cisplatin or carboplatin) plus ipilimumab 10 mg/kg or placebo every 3 weeks for a total of four doses each in a phased induction schedule (chemotherapy in cycles one to four; ipilimumab or placebo beginning in cycle three up to cycle six), followed by ipilimumab or placebo maintenance every 12 weeks. Primary end point was overall survival (OS) among patients receiving at least one dose of blinded study therapy. Results Of 1,132 patients randomly assigned, 954 received at least one dose of study therapy (chemotherapy plus ipilimumab, n = 478; chemotherapy plus placebo, n = 476). Median OS was 11.0 months for chemotherapy plus ipilimumab versus 10.9 months for chemotherapy plus placebo (hazard ratio, 0.94; 95% CI, 0.81 to 1.09; P = .3775). Median progression-free survival was 4.6 months for chemotherapy plus ipilimumab versus 4.4 months for chemotherapy plus placebo (hazard ratio, 0.85; 95% CI, 0.75 to 0.97). Rates and severity of treatment-related adverse events were similar between arms, except for diarrhea, rash, and colitis, which were more frequent with chemotherapy plus ipilimumab. Rate of treatment-related discontinuation was higher with chemotherapy plus ipilimumab (18% v 2% with chemotherapy plus placebo). Five treatment-related deaths occurred with chemotherapy plus ipilimumab and two with chemotherapy plus placebo. Conclusion Addition of ipilimumab to chemotherapy did not prolong OS versus chemotherapy alone in patients with newly diagnosed extensive-stage disease SCLC. No new or unexpected adverse events were observed with chemotherapy plus ipilimumab. Several ongoing studies are evaluating ipilimumab in combination with programmed death-1 inhibitors in SCLC." @default.
• W2480201404 created "2016-08-23" @default.
• W2480201404 creator A5003317297 @default.
• W2480201404 creator A5007653426 @default.
• W2480201404 creator A5007665505 @default.
• W2480201404 creator A5012217431 @default.
• W2480201404 creator A5012937808 @default.
• W2480201404 creator A5018054038 @default.
• W2480201404 creator A5019233587 @default.
• W2480201404 creator A5024261346 @default.
• W2480201404 creator A5029761367 @default.
• W2480201404 creator A5035231990 @default.
• W2480201404 creator A5038306289 @default.
• W2480201404 creator A5038912570 @default.
• W2480201404 creator A5046728958 @default.
• W2480201404 creator A5062894702 @default.
• W2480201404 creator A5067307453 @default.
• W2480201404 creator A5068743826 @default.
• W2480201404 creator A5069095893 @default.
• W2480201404 creator A5070664118 @default.
• W2480201404 creator A5077961608 @default.
• W2480201404 creator A5083662358 @default.
• W2480201404 date "2016-11-01" @default.
• W2480201404 modified "2023-10-18" @default.
• W2480201404 title "Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer" @default.
• W2480201404 cites W1543244809 @default.
• W2480201404 cites W1547463098 @default.
• W2480201404 cites W1809627231 @default.
• W2480201404 cites W1850736485 @default.
• W2480201404 cites W1969969760 @default.
• W2480201404 cites W1982488143 @default.
• W2480201404 cites W1990676527 @default.
• W2480201404 cites W2012403244 @default.
• W2480201404 cites W2055901890 @default.
• W2480201404 cites W2056631765 @default.
• W2480201404 cites W2066671159 @default.
• W2480201404 cites W2080886891 @default.
• W2480201404 cites W2094179246 @default.
• W2480201404 cites W2095826876 @default.
• W2480201404 cites W2097995306 @default.
• W2480201404 cites W2098414192 @default.
• W2480201404 cites W2104347254 @default.
• W2480201404 cites W2108927999 @default.
• W2480201404 cites W2112121482 @default.
• W2480201404 cites W2119198740 @default.
• W2480201404 cites W2120277401 @default.
• W2480201404 cites W2123363005 @default.
• W2480201404 cites W2123589978 @default.
• W2480201404 cites W2123767004 @default.
• W2480201404 cites W2127776375 @default.
• W2480201404 cites W2128758225 @default.
• W2480201404 cites W2143163879 @default.
• W2480201404 cites W2143488876 @default.
• W2480201404 cites W2148706732 @default.
• W2480201404 cites W2152897456 @default.
• W2480201404 cites W2154895535 @default.
• W2480201404 cites W2155599713 @default.
• W2480201404 cites W2156353875 @default.
• W2480201404 cites W2164918836 @default.
• W2480201404 cites W2166662937 @default.
• W2480201404 cites W2167805334 @default.
• W2480201404 cites W2170260373 @default.
• W2480201404 cites W2222086386 @default.
• W2480201404 cites W2253806401 @default.
• W2480201404 cites W2260067559 @default.
• W2480201404 cites W2285109017 @default.
• W2480201404 cites W2289712604 @default.
• W2480201404 cites W2293531514 @default.
• W2480201404 cites W2506231525 @default.
• W2480201404 cites W2566863750 @default.
• W2480201404 doi "https://doi.org/10.1200/jco.2016.67.6601" @default.
• W2480201404 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27458307" @default.
• W2480201404 hasPublicationYear "2016" @default.
• W2480201404 type Work @default.
• W2480201404 sameAs 2480201404 @default.
• W2480201404 citedByCount "407" @default.
• W2480201404 countsByYear W24802014042016 @default.
• W2480201404 countsByYear W24802014042017 @default.
• W2480201404 countsByYear W24802014042018 @default.
• W2480201404 countsByYear W24802014042019 @default.
• W2480201404 countsByYear W24802014042020 @default.
• W2480201404 countsByYear W24802014042021 @default.
• W2480201404 countsByYear W24802014042022 @default.
• W2480201404 countsByYear W24802014042023 @default.
• W2480201404 crossrefType "journal-article" @default.
• W2480201404 hasAuthorship W2480201404A5003317297 @default.
• W2480201404 hasAuthorship W2480201404A5007653426 @default.
• W2480201404 hasAuthorship W2480201404A5007665505 @default.
• W2480201404 hasAuthorship W2480201404A5012217431 @default.
• W2480201404 hasAuthorship W2480201404A5012937808 @default.
• W2480201404 hasAuthorship W2480201404A5018054038 @default.
• W2480201404 hasAuthorship W2480201404A5019233587 @default.
• W2480201404 hasAuthorship W2480201404A5024261346 @default.
• W2480201404 hasAuthorship W2480201404A5029761367 @default.
• W2480201404 hasAuthorship W2480201404A5035231990 @default.
• W2480201404 hasAuthorship W2480201404A5038306289 @default.
• W2480201404 hasAuthorship W2480201404A5038912570 @default.
• W2480201404 hasAuthorship W2480201404A5046728958 @default.

• next